With biotech firms caught in the crosshairs of Trump’s tariffs, the levy could prove to be a boon for domestic producers but a bane for exporters.
When the stock markets in Hong Kong and mainland China resumed trading after a long weekend on Monday, traders knew they were in for a world of pain. Only a few niche healthcare companies emerged unscathed.
Pacific Shuanglin Bio-pharmacy, Beijing Tiantan Biological Products and China Resources Boya Bio-pharmaceutical Group – involved in processing human blood plasma into high-value medical products – gained 10.6 to 16.6 per cent in two days after Beijing announced a matching 34 per cent “reciprocal” tariff imposed by Washington on Chinese goods.
